研究紫杉醇为主的联合化疗在晚期乳腺癌中的临床价值
Clinical Value of Paclitaxel-based Combination Chemotherapy in the Treatment of Advanced Breast Cancer
齐孝友 1李亚彤 1鲁良1
作者信息
- 1. 枣庄市胸科医院(枣庄市肿瘤医院)外科,山东枣庄 277000
- 折叠
摘要
目的 研究紫杉醇为主的联合化疗在晚期乳腺癌中的临床价值.方法 选取2019年10月—2023年9月枣庄市胸科医院(枣庄市肿瘤医院)收治的52例晚期乳腺癌患者为研究对象,按随机数表法分为两组,各26例.对照组采用环磷酰胺与表柔比星治疗,观察组采用紫杉醇为主的联合化疗治疗,对比两组患者治疗效果情况.结果 对照组治疗总有效率为 53.85%,低于观察组的 80.77%,差异有统计学意义(χ2=4.282,P<0.05).观察组生活质量及体力活动评分比对照组更高,差异有统计学意义(P均<0.05);观察组肿瘤标志物数值比对照组更低,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05).结论 对晚期乳腺癌患者采用紫杉醇为主的联合化疗治疗效果优越.
Abstract
Objective To study the clinical value of paclitaxel-based combination chemotherapy in the treatment of advanced breast cancer.Methods A total of 52 patients with advanced breast cancer in Zaozhuang Chest Hospital(Zaozhuang Cancer Hospital)from October 2019 to September 2023 were selected as the study objects,and divided into two groups by random number table method,26 cases in each group.The control group was treated with cyclo-phosphamide and epirubicin,and the observation group was treated with combined chemotherapy based on paclitaxel.The therapeutic effect of the two groups was compared.Results In the control group,the total effective rate of the con-trol group was 53.85%,lower than 80.77%of the observation group,and the difference was statistically significant(χ2=4.282,P<0.05).The scores of quality of life and physical activity in the observation group were higher than the control group,and the differences were statistically significant(both P<0.05).The value of tumor markers in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).The total incidence of ad-verse reactions was compared in two groups,and the difference was not statistically significant(P>0.05).Conclusion Combined chemotherapy based on paclitaxel has a superior therapeutic effect on advanced breast cancer patients.
关键词
乳腺癌/紫杉醇/环磷酰胺/表柔比星/联合化疗Key words
Breast cancer/Paclitaxel/Cyclophosphamide/Epirubicin/Combination chemotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据